SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) April 19, 1999
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
Biocontrol Technology, Inc. announced today, that the
premarket approval application (PMA) Shell for modular
review of its Diasensor 2000 noninvasive glucose
monitor, submitted in late February, has been accepted
by the Food and Drug Administration (FDA). With this
acceptance and assigned PMA Shell number, Biocontrol
can commence submission of the PMA modules, the first
of which is currently being compiled.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired - Not
Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - Press Release.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: April 19, 1999
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.429.0673 phone
1.412.279.9690 fax 1.412.279.5041 fax
BIOCONTROL'S DIASENSOR PMA SHELL ACCEPTED BY FDA
Pittsburgh, PA - April 19, 1999 - Biocontrol Technology,
Inc. (OTCBB:BICO) announced today, that the premarket approval
application (PMA) Shell for modular review of its Diasensor 2000
noninvasive glucose monitor, submitted in late February, has been
accepted by the Food and Drug Administration (FDA). The
Diasensor 2000 is similar to the Diasensor 1000 with enhancements
to the operating software.
With this acceptance and assigned PMA Shell number,
Biocontrol can commence submission of the PMA modules, the first
of which is currently being compiled.
Biocontrol Technology has its corporate offices in
Pittsburgh, PA and is involved in the development and manufacture
of biomedical devices and environmental products. Biocontrol has
the exclusive rights to the research and development and
manufacturing of the Diasensor 2000. Subsidiary Diasensor.com,
Inc., also located in Pittsburgh, PA, owns the patent, marketing
and distribution rights to the sensor.
WEBSITE: www.bico.com
INVESTOR RELATIONS NEWSLINE NUMBER: 1.800.357.6204
